CXCR3 gene as a therapeutic target in colorectal cancer Authors: Seyedeh Zohreh Azarshin, Melina Malmir, Seyedeh Fatemeh Sajjadi, Mehrdad Behmanesh Published: 2025 ABSTRACT BackgroundCancers, especially colorectal cancer, are among the most common and deadly diseases in the world, and their incidence is increasing in various countries. Current therapeutic methods, such as chemotherapy, surgery, and immunotherapy, have failed to provide successful treatment without side effects. Therefore, identifying effective therapeutic targets is crucial. Several studies have demonstrated that the expression of the CXCR3 gene, a member of the GPCR family, is elevated in colorectal cancer.MethodsIn this study, the effect of targeting the CXCR3 gene on the HCT-116 line, a colorectal cancer cell line, was investigated via gene-specific targeting. For this purpose, specific DNAzymes were designed, and the impact of CXCR3 downregulation on cancer cell development was assessed via cell cycle analysis, Annexin V-PI staining, and the wound healing method.ResultsCXCR3 gene downregulation inhibited the key AKT‒MTOR pathway and reduced proliferation and growth of HCT-116 cells. Moreover, CXCR3 mRNA downregulation increased the apoptosis of these cells.ConclusionOur findings suggest that downregulation of CXCR3 mRNA inhibits colorectal cancer cell growth through inhibition of the AKT‒mTOR pathway. The CXCR3 receptor can be considered a new therapeutic target in colorectal cancer therapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15409-w. Introduction According to the World Health Organization (WHO), a significant increase in deaths from colorectal cancer (CRC) and rectal cancer is predicted to occur up to 2035 [1]. CRC is the third most common cancer worldwide, and it is also the second most common cause of cancer death (8–9% of cancer-related deaths) [2, 3]. More than 90% of deaths from cancer are in the metastasis stage [1]. Current therapeutic strategies are based on surgery followed by chemotherapy, radiation therapies, and immunotherapy, all of which have side effects that often significantly impact quality of life. Currently, novel targeted strategies are being developed to improve the efficacy and reduce the toxicity of conventional treatments [4]. G protein-coupled receptors (GPCRs) constitute the largest family of cell surface receptors and play important roles in transmitting signals into the cell. GPCRs have a key impact on many processes, such as proliferation, migration, and cell survival [5]. Therefore, GPCRs have become potential targets for the treatment of many disorders, such as high blood pressure, diabetes, and cancer. In addition, previous studies revealed that altered GPCR expression or mutations are associated with tumor growth and metastasis in different types of cancers [6]. Additionally, as of November 2017, GPCRs are considered the largest family of targets for approved drugs. Among them, C-X-C motif chemokine receptor 3 (CXCR3) is a Gαi protein-coupled receptor in the CXC chemokine receptor family [7]. CXCR3 has a complex and dual effect on cancer, impacting tumor behavior, the immune response, and metastasis, depending on the cancer type and context [8]. CXCR3 and its ligands (CXCR9, CXCR10, and CXCR11) are differentially expressed in patients with cancers such as colorectal, stomach, breast, prostate, kidney, ovarian, esophageal, lung, glioma, osteosarcoma, and myeloma [9] and promote tumor proliferation and metastasis. Under normal physiological conditions, CXCR3 is expressed in immune cells, including activated T cells, NK cells, neutrophils, and endothelial cells, neurons, and astrocytes. CXCR3 can regulate inflammatory response after activation by its ligand through the MAPK/ERK and the PI3 kinase/AKT pathways [10, 11]. These pathways induce chemotaxis of immune cells to sites of inflammation or infection, inflammatory cell recruitment, and supporting immune surveillance and antiviral activities. Moreover, CXCR3 plays a pivotal role in shaping adaptive immune responses via promoting T cell activation, proliferation, and differentiation [10, 11]. But in cancer cells, different variants of CXCR3 can couple with Gαi or Gαs and activate different downstream signaling pathways. Activation of Gαi via CXCR3 induced PI3K/AKT and MAPK/ERK pathways and led to promoting cellular proliferation, migration, and survival, which are mechanisms exploited in tumor progression and metastasis [12]. But couples CXCR3 with Gαs proteins promote anti-proliferative and pro-apoptotic effects, especially in endothelial cells, thus contributing to angiostasis [13, 14]. Moreover, CXCR3 signaling may contribute to cancer cell metastasis and epithelial-to-mesenchymal transition (EMT) via decreasing cell adhesion proteins like E-cadherin and increasing mesenchymal markers, including N-cadherin and vimentin [15]. Also, CXCR3 signaling affects Cytoskeletal reorganization, which enhances invasion and metastatic cancer cells. Previous studies have demonstrated that different variants of CXCR3 have opposite effects on colon cancer and that their interaction may play an important regulatory role in the tumorigenicity of CRC [16]. In the present study, the effect of CXCR3 gene downregulation on the proliferation of colorectal cancer cells was investigated. To achieve this goal, a CXCR3-specific DNAzyme was designed to specifically reduce CXCR3 mRNA expression in the HCT-116 cell line. We subsequently assessed the effect of CXCR3 mRNA downregulation on the AKT‒mTOR signaling pathway, a key regulator of cell growth and survival. Our findings provide insight into the mechanistic role of the CXCR3 gene in colorectal cancer progression and its potential as a therapeutic target. Materials and methods Bioinformatics analysis The overexpression of the CXCR3 gene in colorectal cancer patients was evaluated via the GEPIA2 database. GEPIA2 is an online data web developed for gene expression analysis integrated through the UCSC Xena platform [17]. CXCR3 gene expression in colorectal adenocarcinoma tissue was compared to the TCGA normal tissue based on Log2FC Cutoff of 1 and p-value Cutoff of 0.01. Additionally, the expression profile of the CXCR3 gene across different stages of colorectal adenocarcinoma was also examined via the GEPIA2 database. To evaluate the association between CXCR3 expression and patient survival, a Kaplan‒Meier curve was generated with the Kaplan‒Meier plotter database on the basis of autoselections of the best cutoff. Cell culture The human colorectal cancer cell line HCT-116 was purchased from the Pasteur Institute (Iran). HCT-116 cells were cultured in RPMI (Gibco) supplemented with 10% FBS (fetal bovine serum, Gibco), streptomycin (100 µg/mL), and penicillin (100 U/mL, Gibco). The HCT-116 cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2. CXCR3 mRNA downregulation in HCT-116 cells To investigate the effect of CXCR3 mRNA downregulation on CRC, two specific DNAzymes for targeting CXCR3 mRNA were designed (Table 1). Moreover, a scramble DNAzyme, designed as a non-targeting control with the same 10–23 DNAzyme catalytic loop sequence but lacking homology to any human transcript, was used. The DNAzymes were transfected into HCT-116 cells using Turbofect (Thermo Scientific) reagent according to the manufacturer’s instructions.Table 1Sequences of primers used in this study for investigating gene expression changes via the qPCR techniqueGene nameNCBI accession No.Sequence of primers (5’−3’)PCR product(bp)CXCR3NM_001504.2F: TCTGGCTCTCCCCAATATCCTCGCR: CTCTACGCCATGCCTTGTACTCCC232AKT1NM_001382433.1F:AGAAGGACCCCAAGCAGAGGCR: TGTCCACACACTCCATGCTGTC236MTORNM_001386501.1F: GGGACTGCTTTGAGGTTGCTATGACCR: TCGCAGCACCTCCATCACTGTGTGG151GAPDHNM_002046.7F: CCATGAGAAGTATGACAACR: GAGTCCTTCCACGATACC117DNAzymeNM_001504.25’-GGTACAGCAGGCTAGCTACAACGAGAGTCACT-3’5’-CACGTCTAGGCTAGCTACAACGACCTGCTTT-3 Table 1Sequences of primers used in this study for investigating gene expression changes via the qPCR techniqueGene nameNCBI accession No.Sequence of primers (5’−3’)PCR product(bp)CXCR3NM_001504.2F: TCTGGCTCTCCCCAATATCCTCGCR: CTCTACGCCATGCCTTGTACTCCC232AKT1NM_001382433.1F:AGAAGGACCCCAAGCAGAGGCR: TGTCCACACACTCCATGCTGTC236MTORNM_001386501.1F: GGGACTGCTTTGAGGTTGCTATGACCR: TCGCAGCACCTCCATCACTGTGTGG151GAPDHNM_002046.7F: CCATGAGAAGTATGACAACR: GAGTCCTTCCACGATACC117DNAzymeNM_001504.25’-GGTACAGCAGGCTAGCTACAACGAGAGTCACT-3’5’-CACGTCTAGGCTAGCTACAACGACCTGCTTT-3 Sequences of primers used in this study for investigating gene expression changes via the qPCR technique F: TCTGGCTCTCCCCAATATCCTCGC R: CTCTACGCCATGCCTTGTACTCCC F:AGAAGGACCCCAAGCAGAGGC R: TGTCCACACACTCCATGCTGTC F: GGGACTGCTTTGAGGTTGCTATGACC R: TCGCAGCACCTCCATCACTGTGTGG F: CCATGAGAAGTATGACAAC R: GAGTCCTTCCACGATACC 5’-GGTACAGCAGGCTAGCTACAACGAGAGTCACT-3’ 5’-CACGTCTAGGCTAGCTACAACGACCTGCTTT-3 RNA extraction and cDNA synthesis Total RNA was extracted via the phenol‒chloroform method and RNX Plus solution (SinaClone, Iran) according to the provided protocol. RNA quantity and quality were evaluated via spectrophotometry and gel electrophoresis, respectively. Ultimately, a total of 3 µg of RNA was reverse transcribed with a cDNA reverse transcription kit (Parstous, Iran). Successful cDNA synthesis was confirmed via PCR amplification of the housekeeping gene GAPDH. Gene expression analysis by real-time PCR To assess the changes in the expression of CXCR3, AKT, and mTOR mRNAs, qPCR was performed. The qPCR reactions were carried out in a final volume of 10 µl containing 10 ng of cDNA, 2 µl of Eva green master mix (5X, Solis BioDyne, Estonia), and 4 pM of each forward or reverse primer. The specificity of the PCR products was confirmed via melt curve analysis. The relative gene expression levels were normalized to the internal control gene GAPDH. The expression fold changes of all the mRNAs were calculated via the 2−ΔΔCT method [18]. All primers used in this study are listed in Table 1. All experiments were performed with at least three biological replicates and two technical replicates. Cell cycle analysis To assess the effect of CXCR3 mRNA downregulation on the HCT-116 cell cycle, propidium iodide (PI) staining coupled with flow cytometry was used for cell cycle analysis. Therefore, 4 × 104 HCT-116 cells were seeded in 24-well plates, and after 24 h, cells were transfected with the CXCR3 DNAzyme or the scramble DNAzyme. Forty-eight hours post-transfection, cells were harvested using 0.25% trypsin-EDTA and fixed with 70% cold ethanol. Then, HCT-116 cells were stained with propidium iodide (PI; Sigma) and incubated in the dark at room temperature for 30 min. Finally, DNA content analysis was performed via BD Biosciences flow cytometry. Data were analyzed via FlowJo v.10 software. All experiments were performed with at least three biological replicates. Apoptosis analysis To evaluate the effect of CXCR3 mRNA downregulation on HCT-116 apoptosis, Annexin-V propidium iodide (PI) staining was performed. On 12 well plates, 8 × 104 HCT-116 cells/well were seeded. HCT-116 cells were transfected via the CXCR3 DNAzyme or the scramble control DNAzyme. After 48 h of the transfection, cells were harvested with 0.25% trypsin-EDTA and stained with the Annexin-V FITC Apoptosis Detection Kit (Sigma) according to the manufacturer’s instructions. Finally, the rate of HCT-116 apoptosis was measured via flow cytometry. All results were analyzed via FlowJo v.10 software. An apoptosis assay was performed with at least three biological replicates. Western blotting To investigate the effect of the CXCR3 mRNA downregulation on the protein levels of AKT and mTOR, a western blot technique was used. Forty-eight hours post-transfection, HCT-116 cells were lysed via RIPA buffer (Beyotime Institute of Biotechnology) containing a protease and phosphatase inhibitor cocktail. Protein concentrations were measured via the Bradford assay. Equal amounts of protein (20 µg) were separated by 10% SDS‒PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. Then, the membrane was blocked with 5% skim milk powder and incubated overnight with primary antibodies at 4 °C. After washing, the membranes were incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies. Finally, the protein bands were subjected to chemiluminescence with an enhanced chemiluminescence (ECL) kit (Amersham, UK). For the internal control, GAPDH was used. All the bands were quantified via ImageJ software. The specifics of all the primary antibodies used in this study are listed in Table 2. Table 2Specifications of the primary antibodies used for Western blotting in this studyAntibodyCatalog NumberCompanyp-mTOR (Ser 2481 55.42)sc-293,089Santa Cruz BiotechnologyPhospho-Akt (Ser473) Antibody9271Cell Signaling TechnologyAKTsc-5298Santa Cruz BiotechnologymTORsc-517,464Santa Cruz BiotechnologyGAPDHsc-47,724Santa Cruz Biotechnology Table 2Specifications of the primary antibodies used for Western blotting in this studyAntibodyCatalog NumberCompanyp-mTOR (Ser 2481 55.42)sc-293,089Santa Cruz BiotechnologyPhospho-Akt (Ser473) Antibody9271Cell Signaling TechnologyAKTsc-5298Santa Cruz BiotechnologymTORsc-517,464Santa Cruz BiotechnologyGAPDHsc-47,724Santa Cruz Biotechnology Specifications of the primary antibodies used for Western blotting in this study Wound healing assay To examine the impact of CXCR3 mRNA downregulation on HCT-116 cell migration, a wound healing assay was performed. First, the HCT-116 cells (8 × 104 cells/well) were seeded into a 12-well plate and cultured until reaching approximately 80% confluency. Cells were then transfected with the CXCR3 DNAzyme or the scramble DNAzyme. The cell monolayers were then gently scratched with a scratcher (SPL Lifesciences). Finally, images were captured under an inverted microscope (Olympus Germany) at 0, 24, 48, and 72 h. The percentage of wound closure was estimated via the ImageJ software. All experiments were performed with at least three biological replicates. Statistical analysis To perform the statistical analysis and construct the gene expression graphs, we employed GraphPad Prism 9. An unpaired Student’s t-test was employed to compare the two groups, and P values < 0.05 were considered statistically significant. All the results are expressed as the means ± standard deviations (SDs) of three identical experiments. Results Bioinformatics analysis indicated that CXCR3 was upregulated in colorectal adenocarcinoma RNA-seq analysis between 275 colorectal adenocarcinoma tissues and 349 normal tissues revealed that overexpression of the CXCR3 gene occurs in colorectal adenocarcinoma. Additionally, the expression of CXCR3 is nearly identical across different stages of colorectal cancer. The Kaplan‒Meier plot revealed that patients with high CXCR3 expression had a survival probability of less than 20% after 80 months (Fig. 1 & Figure S1). Fig. 1Confirmation of the upregulation of CXCR3 in colorectal adenocarcinoma via an in silico study. a: Box plot showing that CXCR3 expression was significantly increased in the tumor tissue of patients (n: 275) with colorectal cancer compared to normal tissue (n: 349). b: In the stage plot, the expression of CXCR3 (Log2(TPM + 1)) was compared among different stages of colorectal cancer. c: Kaplan‒Meier plot showing a strong association between CXCR3 expression and survival probability Confirmation of the upregulation of CXCR3 in colorectal adenocarcinoma via an in silico study. a: Box plot showing that CXCR3 expression was significantly increased in the tumor tissue of patients (n: 275) with colorectal cancer compared to normal tissue (n: 349). b: In the stage plot, the expression of CXCR3 (Log2(TPM + 1)) was compared among different stages of colorectal cancer. c: Kaplan‒Meier plot showing a strong association between CXCR3 expression and survival probability CXCR3 mRNA downregulation inhibited the AKT/mTOR signaling pathway To evaluate the effect of CXCR3 mRNA downregulation on colorectal cancer cells, a specific CXCR3 DNAzyme was used. qPCR revealed that the CXCR3 DNAzyme reduced CXCR3 mRNA expression to 30% of the control level (*P < 0.03). Additionally, data showed that CXCR3 mRNA downregulation decreased levels of AKT and mTOR mRNA by approximately 50% and 80%, respectively, with **P < 0.01, *P < 0.05 (Fig. 2a& b). Additionally, western blot data indicated that CXCR3 mRNA downregulation slightly decreased the protein levels of AKT and mTOR by approximately 0.96- and 0.81-fold, respectively. Notably, the levels of the phosphorylated forms of mTOR (P-mTOR) and AKT (P-AKT) were markedly reduced to 0.35- and 0.44-fold of the control, respectively (Fig. 2c&d, Supplementary 1 Figure S2), indicating strong inhibition of the pathway. Also, CXCR3 mRNA downregulation decreased expression of mTOR and AKT mRNA in Caco-2 cell line (Supplementary 2 Figure S1). Fig. 2CXCR3 downregulation decreased the levels of AKT and mTOR. a: Investigation of CXCR3 DNAzyme efficiency to reduce the level of CXCR3 mRNA. b: The expression of AKT and mTOR mRNAs was decreased after CXCR3 mRNA downregulation in the HCT-116 cell line. Real-time PCR was performed to evaluate the effect of CXCR3 mRNA downregulation on the expression of the AKT and mTOR genes (*P < 0.037, **P < 0.0044). The GAPDH gene was used as an internal control to normalize the expression changes in the CXCR3, AKT, and mTOR genes. All experiments were performed with at least three biological replicates and 2 technical replicates. c & d, CXCR3 downregulation decreased p-MTOR and P-AKT at the protein level. Western blot image and densitometry plots showing the fold change relative to the control. All marker intensity values were normalized to the corresponding GAPDH value. Full-length blots are presented in Supplementary 1Figure S2 CXCR3 downregulation decreased the levels of AKT and mTOR. a: Investigation of CXCR3 DNAzyme efficiency to reduce the level of CXCR3 mRNA. b: The expression of AKT and mTOR mRNAs was decreased after CXCR3 mRNA downregulation in the HCT-116 cell line. Real-time PCR was performed to evaluate the effect of CXCR3 mRNA downregulation on the expression of the AKT and mTOR genes (*P < 0.037, **P < 0.0044). The GAPDH gene was used as an internal control to normalize the expression changes in the CXCR3, AKT, and mTOR genes. All experiments were performed with at least three biological replicates and 2 technical replicates. c & d, CXCR3 downregulation decreased p-MTOR and P-AKT at the protein level. Western blot image and densitometry plots showing the fold change relative to the control. All marker intensity values were normalized to the corresponding GAPDH value. Full-length blots are presented in Supplementary 1Figure S2 CXCR3 mRNA downregulation increased apoptosis in HCT-116 cells The effect of CXCR3 mRNA downregulation on colorectal cancer cell apoptosis was assessed by flow cytometry and annexin V-PI staining. CXCR3 mRNA downregulation significantly increased the number of HCT-116 cells in both the late and early apoptotic Phases (**P < 0.002, *P < 0.030). Moreover, the proportion of live cells was significantly decreased in CXCR3 down-regulated cells compared to control cells (**P < 0.004). These results are presented in Fig. 3. Morover, downregulation of CXCR3 mRNA increased apoptosis of Caco-2 cells (Supplementary 2 Figure S2). Fig. 3CXCR3 mRNA silencing induced apoptosis in HCT-116 cells. HCT-116 colorectal cancer cell lines were transfected with specific DNAzymes for CXCR3 or the scramble DNAzyme as a control for 24 h and then subjected to Annexin V-PI staining and flow cytometry analysis. a: Flow cytometry plot showing specific cell populations (live, early apoptosis, and late apoptosis) in the control group of HCT-116 cells. b: Flow cytometry plot of HCT-166 cells after CXCR3 mRNA downregulation. c: Bar graphs showing the percentage of apoptotic colorectal cancer cell lines. (*P < 0.05, **P < 0.008). All data belong to at least three independent biological replicates CXCR3 mRNA silencing induced apoptosis in HCT-116 cells. HCT-116 colorectal cancer cell lines were transfected with specific DNAzymes for CXCR3 or the scramble DNAzyme as a control for 24 h and then subjected to Annexin V-PI staining and flow cytometry analysis. a: Flow cytometry plot showing specific cell populations (live, early apoptosis, and late apoptosis) in the control group of HCT-116 cells. b: Flow cytometry plot of HCT-166 cells after CXCR3 mRNA downregulation. c: Bar graphs showing the percentage of apoptotic colorectal cancer cell lines. (*P < 0.05, **P < 0.008). All data belong to at least three independent biological replicates CXCR3 mRNA downregulation induced S-phase arrest in HCT-116 cells The impact of CXCR3 downregulation on the cell cycle distribution of colorectal cancer cell lines was investigated by PI staining followed by flow cytometry analysis. The data revealed that CXCR3 mRNA downregulation reduced the percentage of cells in the G1 and G2 phases. CXCR3 mRNA downregulation significantly suppressed cell propagation via inducing S-phase arrest (*P < 0.013, Fig. 4). Additionally, similar result observed after CXCR3 mRNA downregulation in Caco-2 cells. (Supplementary 2 Figure S3). Fig. 4CXCR3 mRNA downregulation arrested HCT-116 cell propagation. HCT-116 cells after transfection with CXCR3 DNAzyme or Scrambled control DNAzyme were stained with PI. Then, the DNA content was analyzed by flow cytometry, and the percentages of cells in the G1, S, and G2/M phases of the cell cycle are shown. There is an arrest in the S phase, which decreases cell proliferation (*P < 0.05). a: Graph of the DNA content of the control group. b: Graph of the DNA content of the CXCR3-downregulated group. c: Bar graph of the percentage of DNA content in the two groups. All data belong to at least three independent biological replicates CXCR3 mRNA downregulation arrested HCT-116 cell propagation. HCT-116 cells after transfection with CXCR3 DNAzyme or Scrambled control DNAzyme were stained with PI. Then, the DNA content was analyzed by flow cytometry, and the percentages of cells in the G1, S, and G2/M phases of the cell cycle are shown. There is an arrest in the S phase, which decreases cell proliferation (*P < 0.05). a: Graph of the DNA content of the control group. b: Graph of the DNA content of the CXCR3-downregulated group. c: Bar graph of the percentage of DNA content in the two groups. All data belong to at least three independent biological replicates CXCR3 mRNA downregulation reduced the proliferation of HCT-116 cells A wound-healing assay was conducted to investigate the effect of CXCR3 mRNA downregulation on the proliferation of HCT-116 cancer cells. The results revealed that the downregulation of CXCR3 mRNA led to a significant decrease in the proliferation of HCT-116 cells. Data showed that more than 90% of the scratches in the control group were closed after 72 h, whereas the wound closure in CXCR3 mRNA-downregulated cells remained incomplete at the same time point (**P < 0.004, Fig. 5). Fig. 5CXCR3 mRNA downregulation reduced scratch wound healing in HCT-116 cells. HTC-116 cells were transfected with CXCR3 DNAzyme or Scrambled DNAzyme, then images of scratch wound closure were captured via an inverted microscope, and analysis of the percentage of scratch wound closure was performed by ImageJ. a: light images of scratch wound healing in 0 h, 24 h, 48 h, and 72 h. b: graph of percentage of scratch wound closure. c: bar graph of fold change of scratch wound closure in different time points (CXCR3 downregulated compared to control groups). Images were taken using a 10X objective. All data belong to at least three independent biological replicates. (**P < 0.004) CXCR3 mRNA downregulation reduced scratch wound healing in HCT-116 cells. HTC-116 cells were transfected with CXCR3 DNAzyme or Scrambled DNAzyme, then images of scratch wound closure were captured via an inverted microscope, and analysis of the percentage of scratch wound closure was performed by ImageJ. a: light images of scratch wound healing in 0 h, 24 h, 48 h, and 72 h. b: graph of percentage of scratch wound closure. c: bar graph of fold change of scratch wound closure in different time points (CXCR3 downregulated compared to control groups). Images were taken using a 10X objective. All data belong to at least three independent biological replicates. (**P < 0.004) Discussion GPCRs have emerged as a novel therapeutic target for cancer treatment. Among all GPCRs, the CXCR3 receptor is a chemokine receptor with known ligands, including CXCL9, CXCL10, and CXCL11, which have roles in cancer prognosis and therapeutic methods for treating CRC [19–21]. Our bioinformatics study revealed that CXCR3 mRNA expression was significantly upregulated in colorectal adenocarcinoma, aligning with previous reports showing higher expression levels of CXCR3 in advanced tumors of CRC [2]. The CXCR3 gene has been proposed as a potential diagnostic marker and therapeutic target in several solid tumors, including gastric cancer [22]. Another study demonstrated that elevated levels of CXCR3 are associated with the tumor size, cell differentiation, invasion, and metastasis of liver cancer tumor cells [23]. The PI3K/AKT/mTOR pathway is one of the pathways that have a vital role in the proliferation, apoptosis, and survival of CRC cells [24], and its targeting can reduce tumor development [25–29]. Previous studies have indicated that targeting the PI3K/AKT/mTOR pathway reduces the invasion, migration, and metastasis of CRC [24, 30, 31]. Therefore, in the present study, the impact of CXCR3 mRNA downregulation on the proliferation and apoptosis of HCT-116 cells via the PI3K/AKT/mTOR pathway was evaluated. The present study demonstrated that CXCR3 mRNA downregulation decreased AKT and MTOR mRNA expression and significantly reduced phosphorylation of their protein products in HCT-116 cells, attenuating the AKT/mTOR signaling pathway. Consistent with these findings, other studies have indicated that CXCR3 induces AKT activation in tongue squamous cell carcinoma and bladder cancer [15, 32]. Additionally, it confirmed that the CXCL10/CXCR3 axis activates the PI3K/AKT pathway and subsequently affects metastasis and epithelial‒mesenchymal transition (EMT) [3]. CXCR3 downregulation decreases AKT and mTOR phosphorylation, thereby inhibiting the mTOR-AKT signaling pathway and reducing signals that promote cell growth and survival. Additionally, another study on HCC cells demonstrated that the CXCR3 A variant enhanced cell proliferation, migration, and invasion by activating downstream signaling pathways, including the PI3K/AKT and ERK1 pathways [33]. Our data revealed that CXCR3 mRNA downregulation decreased HCT-116 cell proliferation by inducing S-phase arrest, which was accompanied by a reduction in the proportion of cells in the G1 and G2 phases, potentially due to inhibiting the AKT/mTOR pathway. These findings align with those of previous studies showing that targeting the PI3K/AKT/mTOR pathway inhibits tumor growth and enhances sensitivity to CRC therapy [34]. In another cancer cell (lung cancer), a reduced expression of CXCR3 leads to inhibiting cell growth and proliferation [35]. In addition, our data revealed that CXCR3 mRNA downregulation increased HCT-116 apoptosis. In osteosarcoma cancer cells, it has been reported that CXCR3 regulates the signaling of cell apoptosis [36]. In summary, our survival analysis of patients with colorectal cancer showed that high expression of CXCR3 is associated with decreased survival probability. CXCR3 mRNA downregulation induces cell cycle arrest, thereby halting cell proliferation and triggering apoptosis, potentially through the inhibition of the PI3K/AKT/mTOR signaling pathway. However, prior studies have shown that an increased level of CXCR3 is related to improved outcomes in patients with gastric cancer, but another study indicated that the upregulation of CXCR3 promotes gastric cancer cell invasion and migration [37, 38]. This difference may be due to CXCR3 activation through different mediators and the initiation of different intracellular pathways in gastric cancer cells. In addition to the AKT/mTOR pathway highlighted in our study, CXCR3 activates multiple downstream signaling pathways that contribute to the progression and invasion of colorectal cancer. CXCR3A and CXCR3B, two CXCR3 splice variants, have distinct functions in the regulation of cellular functions like invasion, migration, and proliferation by activating various signaling pathways downstream, such as MAPK/ERK and PI3K/AKT, which can modulate cytoskeletal reorganization and EMT [39–41]. Also, CXCL10/CXCR3 increased the colorectal cancer cells’ invasions via triggering small GTPases such as RhoA and cdc42 [3]. Additionally, CXCR3 can interact with other chemokine receptors like CXCR4. CXCR3-CXCR4 heteromeric formation promotes the invasion and metastasis of cancer cells through stabilizing CXCR4 on the surface of cancer cells and inhibiting CXCR4 internalization. This cross-talk exacerbates tumor growth [42]. Also, high CXCR3 expression in microenvironments of tumors like lymph nodes and metastatic liver lesions is correlated with poor clinical outcomes and increased tumor metastasis via modulation of immune cell infiltration and tumor-stroma interactions [43]. Due to multimodal signaling roles of CXCR3, comprehensive functional studies, including phosphorylation assays, ligand stimulations, and cross-pathway analyses, are important to uncover the full roles of CXCR3-mediated oncogenic signaling for targeted therapeutic strategies. Despite these findings, our study suffers from some limitations, including the validation of CXCR3 downregulation at protein levels. Moreover, the fact that the assessment of the effects of CXCR3 targeting in other colorectal cancer cells can provide valuable insights into the therapeutic target efficiency of CXCR3 at different stages of colorectal cancer. Moreover, the use of rescue experiments with a CXCR3 agonist can provide strong validation of the impact of the CXCR3 gene. Investigation of the effect of targeting CXCR3 in animal models of colorectal cancer confirms the therapeutic effect of CXCR3. Nevertheless, a limitation of this study is that the activation of other downstream pathways, such as MAPK/ERK and Rho GTPase, which are also influenced by CXCR3, was not explored. Further mechanistic investigations, including pathway-specific phosphorylation assays and ligand stimulation experiments, are necessary to fully elucidate the comprehensive signaling network mediated by CXCR3 in colorectal cancer. Conclusions In conclusion, GPCR has many attractive features for targeted therapy for various kinds of cancers. The CXCR3 GPCR is implicated in colorectal cancer progression via activation of multiple downstream pathways, including but not limited to the AKT/mTOR axis. While our study highlights the involvement of the AKT/mTOR pathway following CXCR3 mRNA downregulation, other pathways downstream of CXCR3, such as MAPK/ERK and Rho GTPase-mediated cytoskeletal changes, may also contribute to cancer progression and warrant further investigation. Therefore, targeting the CXCR3 gene in colorectal cancers with overexpressed CXCR3 levels potentially may hold new therapeutic potential, but more comprehensive studies are necessary to elucidate the breadth of CXCR3-mediated signaling in cancer cells fully. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.